Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > What you see now

<< Previous

Bullboard Posts

Next >>

Comment by Hideawayon Jun 19, 2021 9:02am

185 Views

Post# 33416391

RE:RE:RE:RE:RE:What you see now

The selling certainly had a negative affect on the share price.There is no way to discern the exact percentage but my guess is that it was well over 50% of the cause.Dan and the Director would have been aware of this before the disposition but obviously did not care.I also agree that at the very least shareholders were/are entitled to an explanation but don't hold your breath.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023